A comprehensive view of Pfizer Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer, Roivant Sciences announce Priovant Therapeutics JV; Priovant focused on developing autoimmune disease therapies including oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1to treat multiple severe autoimmune diseases

Pfizer reports combination COVID-19 booster based on original vaccine with omicron-specific protection and omicron-specific booster vaccine both increase omicron-fighting antibodies in tests; omicron-specific booster had strongest response against omicron

Fitch: Covid-19 vaccine sales saw strong start to 2022, with Pfizer and Moderna posting stronger-than-expected Q1 sales; 2022 sales could be comparable to significant 2021 numbers, but estimates for 2023 should see more pronounced decrease in market size

Analysts on Enanta suing Pfizer over Covid pill Paxlovid: SVB Securities says it's unclear whether Enanta is in the right, noting patent dates might not prove who 'invented' technology first; RBC says it could take years for lawsuit to reach conclusion

Enanta files suit in US District Court against Pfizer seeking damages for copyright infringement related to Paxlovid nirmatrelvir, ritonavir tablets; Enanta applied for a patent for a coronavirus protease inhibitor in 2020 and received patent this month

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count